News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase I
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 1/23/2015
Minerva Neurosciences, Inc. (NERV) Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist For Treatment Of Sleep Disorders Including Primary And Comorbid Insomnia 1/22/2015
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2 1/22/2015
Disneyland Measles Outbreak Casts Shadow on Anti-Vaccination Movement 1/21/2015
Tekmira (TKMR) Initiates Phase I Clinical Trial Of TKM-HBV 1/21/2015
Adocia Initiates A Clinical Study On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro Insulin Formulation 1/21/2015
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-391 Ointment For Actinic Keratosis In A Phase 1 Clinical Study 1/20/2015
Tobira Therapeutics Inc. Doses First Subject In Phase 1 Clinical Trial Of Cenicriviroc And Pioglitazone 1/20/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
Immunomedics, Inc. (IMMU) Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) In Patients With Metastatic Gastrointestinal Cancers 1/20/2015
Kite Pharma, Inc. (KITE) Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 1/20/2015
Verastem, Inc. (VSTM) Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 1/20/2015
Cellceutix (CTIX) Reports Spleen Lesion "Disappears" In Patient With Metastatic Stage 4 Ovarian Cancer In Clinical Trial Of Anti-Cancer Drug Kevetrin 1/20/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium 1/19/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
J.P. Morgan: Five Prime Therapeutics, Inc. (FPRX) CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company (BMY) 1/16/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Antibe Therapeutics Inc. (ATE.V) Suspends Its Phase I Clinical Trial Due To Safety Concerns 1/16/2015
Pfizer (PFE)'s Working on Once-a-Year Anti-Cholesterol Shot 1/15/2015
Auspex Pharmaceuticals (ASPX) Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Tourette Syndrome In The Pediatric Population 1/15/2015
OncoMed Pharmaceuticals, Inc. (OMED) Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors 1/15/2015
Novan Therapeutics To Present Successful Clinical Study Results Of Lead Product Candidate SB204 For The Treatment Of Acne Vulgaris 1/15/2015
Newron Pharmaceuticals (NWRN) Announces Results Of Phase I Study Of NW-3509 Phase II Study In Schizophrenia Patients Planned For Q2 2015 1/15/2015
Aptose Biosciences Doses First Patient In Phase 1b Clinical Study Of APTO-253 In Relapsed Or Refractory Hematological Malignancies 1/14/2015
Ascendis Pharma A/S Announces Initiation Of A Phase 1 Single Ascending Dose Study Of Transcon Treprostinil 1/14/2015
Sarepta (SRPT) Announces First Patient Dosed In European Phase1/2 Study Of SRP-4053 In Duchenne Muscular Dystrophy Patients 1/14/2015
BioLine Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 1/14/2015
BioMarin (BMRN) Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study Of BMN 190 For Treatment Of CLN2 Disorder, A Form Of Batten Disease 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015
PsiOxus Therapeutics Limited Release: European Medicines Agency Grants Positive Opinion For Orphan Drug Status For Ovarian Cancer Oncolytic Vaccine 1/13/2015
Bellicum Pharmaceuticals, Inc. Announces Successful Dosing Of First Patient Cohort With BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell Transplant 1/13/2015
Auspex Pharmaceuticals (ASPX) Announces Favorable Topline Results From Thorough QT Clinical Trial Of SD-809 1/12/2015
Lipocine Inc. (LPCN) Announces Positive Phase 1b Top-Line Results With LPCN 1107 In Pregnant Women 1/12/2015
Second Genome Advances Lead Microbiome Drug Development Program In Phase I Clinical Trial As A Treatment For Inflammatory Bowel Disease 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Metastatic Colorectal Cancer 1/12/2015
Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study 1/12/2015
ProteoTech Is Granted Orphan Drug Designation For Systebryl™ (PTI-110) For The Treatment Of AL Amyloidosis 1/12/2015
Scancell To Provide Positive SCIB1 Phase 1/2 Clinical Trial Update During Corporate Presentations 12-15 January, San Francisco 1/12/2015
FDA Approves Cytori Therapeutics, Inc. (CYTX) U.S. Pivotal Scleroderma Trial 1/12/2015
Alnylam Pharmaceuticals (ALNY) Reports Initial Evidence For Potential Correction Of The Hemophilia Phenotype In Phase 1 Study Of ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia 1/12/2015
ReVance Therapeutics, Inc. (RVNC) Announces Publication of Positive Results From RT002 Phase 1/2 Study 1/9/2015
Journal Of Cardiovascular Pharmacology Publishes Positive Nonclinical Results Of Proteon Therapeutics, Inc. (PRTO)'s PRT-201 In Peripheral Artery Disease 1/9/2015
SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus 1/9/2015
TONIX Pharmaceuticals, Inc. (TNXP) Announces Clinical Progress On Potential Treatment for Headache 1/9/2015
Regen BioPharma Identifies Second Generation Gene Silencing Candidates For Blocking Cancer Stem Cell Gene Target 1/9/2015
CoMentis, Inc. And Anvyl Announce The Initiation Of Clinical Trials For APN1125 For The Treatment Of Schizophrenia 1/9/2015
BEAT BioTherapeutics dATP Technology Improves Cardiac Function In End Stage Human Heart Failure Cardiac Muscle 1/9/2015
TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/9/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Interim Data From Phase 1/2 Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease 1/8/2015
Karyopharm Therapeutics (KPTI) Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma 1/8/2015
First Patient Successfully Transplanted With Cryopreserved (Frozen) Nicord® In Gamida Cell Ltd.'s Ongoing Phase I/II Clinical Trial For Blood Cancers 1/8/2015
Cleave Biosciences Initiates Phase 1 Clinical Trial Of CB-5083 In Patients With Advanced Solid Tumors 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology 1/8/2015
Targovax Reports Completion Of Recruitment Of Patients In The Phase 1/2 Clinical Trial CT TG01-01 1/8/2015
Principia Biopharma Successfully Completes Phase 1 Clinical Trial Of PRN1008, A Novel Oral BTK Inhibitor For Autoimmune Diseases 1/8/2015
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 Is Safe With Potential For Therapeutic Effect On Fibrosis In NASH Patients With Advanced Fibrosis 1/7/2015
Arena Pharmaceuticals, Inc. (ARNA) Reports Positive Results From Phase 1b Clinical Trial Evaluating APD334 For The Treatment Of Autoimmune Diseases 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
Cortice Biosciences Announces Enrollment Of A Phase 1 Trial Evaluating TPI 287 Plus Radiotherapy For Treatment Of Lung And Breast Cancer Metastases To The Brain 1/7/2015
Johnson & Johnson (JNJ) Starts Ebola Vaccine Testing in Humans 1/6/2015
Johnson & Johnson (JNJ) Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen 1/6/2015
GliaCure Completes Phase 1a Clinical Trial In Alzheimer's Disease 1/6/2015
Celsion Corporation (CLSN) Submits DNA-Based Immunotherapy Clinical Protocol To The FDA As Part Of A First Line Treatment For Ovarian Cancer 1/6/2015
Inovio Pharmaceuticals (INO) HIV Immunotherapy Shows Characteristics Considered Vital To Treating HIV 1/6/2015
cCAM Biotherapeutics Receives FDA Approval To Initiate Phase 1 Trial For CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 1/6/2015
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 1 Clinical Trial For The Ebola Vaccine Regimen Of MVA-BN® Filo And Janssen's AdVac® technology 1/6/2015
BioLineRx Ltd. Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment 1/6/2015
Cleveland Biolabs Inc. (CBLI) And Incuron Announce Updates On Clinical Progress With Curaxin CBL0137 1/6/2015
Anavex Life Sciences Corp. (AVXL.OB) Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor 1/6/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
Merck & Co. (MRK), NewLink Genetics Ebola Vaccine Trial Resumes in Geneva 1/5/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
OncoMed Pharmaceuticals, Inc. (OMED) Doses First Patient In Phase 1 Clinical Trial Of Novel Anti-DLL4/VEGF Bispecific Antibody 1/5/2015
Alnylam Pharmaceuticals (ALNY) Files Clinical Trial Application To Initiate A Phase 1 Study For ALN-AS1, A Subcutaneously Administered, Investigational Rnai Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias 1/5/2015
Tekmira (TKMR) Provides Update On TKM-PLK1 Phase I/II Clinical Study In Patients With Advanced Gastrointestinal Neuroendocrine Tumors And Adrenocortical Carcinoma 12/31/2014
Idera Pharmaceuticals, Inc. (IDRA) Provides Key Updates On Clinical Development Of IMO-8400 For Treatment Of Waldenstrom's Macroglobulinemia 12/30/2014
Synthetic Biologics, Inc. (SYN) Announces First Patient Dosed In Phase 1b Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/30/2014
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014
AEterna Zentaris (AEZS): Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-361 In A Phase 1 Clinical Study 12/24/2014
Novastem Treats First Patient Using Stemedica Cell Technologies, Inc.'s Mesenchymal And Neural Stem Cell Combination Therapy For Ischemic Stroke 12/24/2014
Mirati Therapeutics  (MRTX) Doses First Patient In Expansion Cohorts Of Phase 1b Trial Of MGCD265 In Genetically Selected Patients 12/23/2014
Helix Biopharma (TSX:HBP) Announces Initiation Of First Clinical Site For US Study 12/23/2014
Tekmira (TKMR) Receives Clearance To Conduct A Phase I Clinical Study With TKM-HBV 12/22/2014
New Published Data Show Pluristem Therapeutics (PSTI)'s PLX Cells Protect Neurons 12/22/2014
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1a Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/22/2014
Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use Of Dermal Sheath Cup Cells To Treat Pattern Baldness 12/22/2014
Relmada Therapeutics Doses First Cohort Of Subjects In Human Clinical Trial Of D-Methadone 12/22/2014
AGA's GERD Registry Enrolls First Patients 12/22/2014
ContraFect Corporation (CFRXU) Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections 12/22/2014
Galapagos NV (GLPG.BR) Initiates First Phase 1 Study In Cystic Fibrosis And Will Receive Milestone Payment From AbbVie (ABBV) 12/19/2014
Curis, Inc. (CRIS) Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors 12/18/2014
Inovio Pharmaceuticals (INO) Initiates DNA Immunotherapy Trial For Breast, Lung And Pancreatic Cancers 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014
Dyax Corp. (DYAX)'s First-In-Human Trial For DX-2930 Conducted By Vince And Associates Clinical Research Featured In The Annals Of Allergy, Asthma & Immunology 12/18/2014
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014
Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data From Phase 1b Trial Of I.V. CR845 In Dialysis Patients 12/17/2014
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors 12/17/2014
Clementia Initiates First Prospective Natural History Study In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 12/17/2014
Capstone Therapeutics (CAPS) Announces Phase 1b/2a Study Results For AEM-28 Showing Safety And Biomarker Efficacy Signals 12/16/2014
TetraLogic Pharmaceuticals (TLOG) Provides Update On Ovarian Cancer Study 12/16/2014
Hemispherx Biopharma (HEB)'s Ampligen® Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
Prothena Receives FDA Fast Track Designation For NEOD001, A Monoclonal Antibody For The Treatment Of Patients With AL Amyloidosis 12/16/2014
Alla Chem Completes Phase Ib/Iia Clinical Study With AV4025, An HCV NS5A Inhibitor 12/16/2014
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase 1 Clinical Trial Of BCX4430 For The Treatment Of Hemorrhagic Fever Viruses 12/15/2014
Cerulean Pharma Inc. (CERU) Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma 12/15/2014
Alkermes plc (ALKS) Announces Initiation Of Clinical Study Of Extended Durations Of Aripiprazole Lauroxil For Treatment Of Schizophrenia 12/15/2014
Complexa Initiates Phase 1B Study Of CXA-10 In Acute Kidney Injury 12/15/2014
Immunomedics, Inc. (IMMU) Reports Expanded Phase 1/2 Trials Confirm Activity And Good Safety Profile Of Sacituzumab Govitecan (Immu-132) In Patients With Advanced Triple-Negative Breast Cancer 12/12/2014
Synta Pharmaceuticals (SNTA) Announces Presentation Of Results From An Investigator-Sponsored Phase 1 Trial Of Ganetespib In HER2+ Metastatic Breast Cancer At The 2014 San Antonio Breast Cancer Symposium 12/12/2014
Oncothyreon Inc. (ONTY) Announces Presentation Of Positive ONT-380 Data At San Antonio Breast Cancer Symposium 12/12/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Sorafenib In Advanced Hepatocellular Carcinoma 12/11/2014
Calithera Biosciences, Inc. (CALA) Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition In Tumor Biopsy Samples From Patients Treated With CB-839 12/11/2014
Vical Incorporated (VICL) Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial 12/11/2014
Radius (RDUS) Presents RAD1901 Data At 2014 San Antonio Breast Cancer Symposium 12/11/2014
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Initiation Of Phase 1 Clinical Trial For ALN-Pcssc, A Subcutaneously Administered Investigational Rnai Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 12/11/2014
Atterocor Expands Phase 1 Trial Of ATR-101 To Additional Leading Adrenal Cancer Centers 12/11/2014
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
bluebird bio (BLUE) Skyrockets Almost 70% On Blood Disease Data 12/10/2014
Arno Therapeutics Doses First Patient In Expansion Stage Of Modified Phase 1/2 Trial Evaluating Onapristone In Progesterone Receptor Positive Tumors 12/10/2014
ARCA biopharma Receives FDA Orphan Drug Designation For rNAPc2 As A Potential Treatment For Ebola 12/10/2014
TiGenix Starts Phase I Trial Of Cx611 In Severe Sepsis 12/10/2014
Omni Bio Pharmaceutical Announces Encouraging Clinical Data For Use Of Alpha-1 Antitrypsin (AAT) In Steroid-Resistant Graft Versus Host Disease 12/10/2014
Alizé Pharma Announces Positive Results For AZP-531, Its Unacylated Ghrelin Analog, From Two Phase I Clinical Trials In Healthy Volunteers And Obese Subjects 12/10/2014
Can-Fite BioPharma (CFBI) To Initiate The Development Program Of Its Next Generation Drug Cf602 12/9/2014
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Cara Therapeutics, Inc. (CARA)' CR845 Peptide For Acute And Chronic Pain In Phase 1a / 1b Trial 12/9/2014
Seattle Children's Research Institute's Reprogrammed T Cell Immunotherapy Clinical Trial Boasts 85% Complete Remission Rate In Children With Relapsed Leukemia 12/9/2014
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Cancer Patients 12/9/2014
bluebird bio (BLUE) Announces Data Demonstrating First Four Patients With ß-Thalassemia Major Treated With LentiGlobin® Are Transfusion-Free 12/9/2014
Agios Pharmaceuticals (AGIO) Reports Positive Phase 1 Data In Healthy Volunteers For AG-348, A First-In-Class Investigational Medicine That Targets The Underlying Cause Of Pyruvate Kinase (PK) Deficiency 12/9/2014
Seattle Genetics, Inc. (SGEN) Presents Data From Novel Antibody-Drug Conjugate SGN-CD33A At American Society of Hematology Annual Meeting 12/9/2014
Calithera Biosciences, Inc. (CALA) Presents Preclinical Study Findings For CB-839 At The 56th American Society of Hematology Annual Meeting 12/9/2014
Karyopharm Therapeutics (KPTI) Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At American Society of Hematology 2014 Annual Meeting 12/9/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS At American Society of Hematology Annual Meeting 12/9/2014
Karyopharm Therapeutics (KPTI) Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At American Society of Hematology 2014 Annual Meeting 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Preliminary Data From Ongoing Phase I/II Dose Escalation Study Of TG-1101 (Ublituximab) In Combination With TGR-1202 In Heavily Pre-Treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity And Safety 12/9/2014
Idera Pharmaceuticals, Inc. (IDRA) Presents Data Supporting IMO-8400 As Novel Therapy For Genetically Defined Forms Of B-Cell Lymphoma At Annual American Society of Hematology Meeting 12/9/2014
Acetylon Pharmaceuticals Announces Ricolinostat Continues To Demonstrate Clinically Meaningful And Durable Disease Response Rates In Phase 1b Combination Studies In Multiple Myeloma 12/9/2014
Jazz Pharmaceuticals (JAZZ) And Concert Pharmaceuticals, Inc. (CNCE) Provide JZP-386 Program Update 12/9/2014
Alnylam Pharmaceuticals (ALNY) Reports Positive Initial Results For ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders, From Ongoing Phase 1 Trial 12/9/2014
Sevion Therapeutics Presents Results Of SNS01-T Phase 1b/2a Dose Escalation Study At American Society of Hematology Annual Meeting 12/9/2014
Infinity Pharmaceuticals Inc. (INFI) Reports New Results From Phase 1 Study Of Investigational Oncology Compound Duvelisib At The American Society of Hematology Annual Meeting 12/9/2014
Juno Therapeutics’s CAR T and TCR Investigational Product Candidates Demonstrate Promising Outcomes In Clinical Trials In Patients With B-Cell Cancers 12/9/2014
Epizyme (EPZM) DOT1L Inhibitor EPZ-5676 Shows Clinical And Biological Activity In Adult Patients With Acute Leukemias In Phase 1 Trial 12/9/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial 12/9/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Follow-Up Data From Phase 1 And PACE Trials Of Ponatinib In Patients With T315I Mutation In Chronic Myeloid Leukemia 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 12/8/2014
Cornerstone Pharmaceuticals, Inc. Commences Phase I Clinical Trial Of CPI-613 For The Treatment Of B-Cell Non-Hodgkin Lymphoma 12/8/2014
Cellerant Therapeutics, Inc. To Present Phase 1 Clinical Data On Evaluation Of CLT-008 In Patients With Acute Myeloid Leukemia At The 2014 American Society of Hematology Annual Meeting 12/8/2014
Agios Pharmaceuticals (AGIO) Announces New Data From Ongoing Phase 1 Trial Of AG-221 Showing Robust Clinical Activity In Patients With Advanced Hematologic Malignancies 12/8/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
VaxInnate Corporation Initiates Phase 1b/2 Clinical Trial Of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, In Elderly 12/8/2014
Affimed Therapeutics AG (AFMD) Presents Final Data For AFM13 Phase 1 Trial At American Society of Hematology 12/8/2014
NKT Therapeutics Inc. Presents Data On Its Therapeutic Program Targeting Sickle Cell Disease At The American Society of Hematology 12/8/2014
Henry Ford Hospital Recruiting Patients For Clinical Trial Which Showed Promising Overall Survival In Recurrent Brain Cancer Patients 12/8/2014
Infinity Pharmaceuticals Inc. (INFI) Reports New Translational Research And Updated Phase 1 Data Of Investigational Oncology Compound Duvelisib At American Society of Hematology Annual Meeting 12/8/2014
Seattle Genetics, Inc. (SGEN) Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations In Frontline And Salvage Hodgkin Lymphoma At American Society of Hematology Annual Meeting 12/8/2014
Alnylam Pharmaceuticals (ALNY) Files Clinical Trial Application (CTA) For ALN-CC5, An Rnai Therapeutic Targeting Complement C5 In Development For The Treatment Of Complement-Mediated Diseases 12/8/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data Show Idarucizumab* Reverses Anticoagulant Effects Of Dabigatran (PRADAXA) In Middle-Aged, Elderly And Renally Impaired Volunteers 12/8/2014
Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology 12/8/2014
Seattle Genetics, Inc. (SGEN) Presents Data From SGN-CD19A Antibody-Drug Conjugate At American Society of Hematology Annual Meeting 12/8/2014
Triphase Accelerator Announces Its Proteasome Inhibitor Marizomib Demonstrates Potent Synergistic Anti-Multiple Myeloma Activity In Combination With Pomalidomide 12/8/2014
Bristol-Myers Squibb Company (BMY) Release: Opdivo (nivolumab) Demonstrates High Overall Response Rate Of 87% for Treatment Of Relapsed Or Refractory Hodgkin Lymphoma 12/8/2014
ImmunoGen, Inc. (IMGN) Announces Encouraging IMGN529 Clinical Data Presented At 56th American Society of Hematology Annual Meeting and Exposition 12/8/2014
Cellular Biomedicine Group (CBMG) Releases Positive 48-Week Data From Phase I/2a Clinical Trial For Rejoin(TM) Treatment Of Knee Osteoarthritis (KOA) 12/5/2014
OncoSec Medical Inc. Reports ImmunoPulse May Prolong Survival Based On Analysis Of Long-Term Survival Data From Phase I Study In Melanoma 12/5/2014
Five Prime Therapeutics, Inc. (FPRX) Initiates Patient Dosing In Phase 1 Clinical Trial Evaluating FPA144 In Gastric Cancer 12/5/2014
Bavarian Nordic (BAVA.CO) Announces First Subject Dosed With Mva-Bn Filo In A Phase 1 Study Investigating A New Prime-Boost Regimen Of Ebola Candidate Vaccines 12/4/2014
University of Michigan To Study GlycoMimetics, Inc. (GLYC)’ GMI-1271 As Potential Treatment For Serious Blood-Clotting Disorder 12/4/2014
VAXIMM Reports Positive Follow-On Data From Oral Cancer Vaccine Trial 12/4/2014
Set Point Medical Announces First Trial Of Bioelectronic Therapy To Treat Crohn’s Disease 12/4/2014
Cara Therapeutics, Inc. (CARA) Announces Positive Top-Line Results From Phase 1a / 1b Trial Of Tablet Formulation Of Oral CR845 For The Treatment Of Acute And Chronic Pain 12/3/2014
Rhizen Pharmaceuticals S.A. To Present Phase 1 Clinical And Additional Preclinical Data Of RP6530 (Dual PI3K Delta/Gamma Inhibitor) In Hematological Malignancies 12/3/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Nab-Paclitaxel And Gemcitabine In Advanced Pancreatic Cancer 12/3/2014
Syntethic Biologics, Inc. Announces First Patient Dosed In Phase 1a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/2/2014
CollPlant Launched A Clinical Trial With VergenixFG; A Gel Based On A Human Collagen For The Treatment Of Chronic Wounds 12/2/2014
AstraZeneca PLC (AZN) And Eli Lilly (LLY) Move Alzheimer's Drug Into Big Trial 12/1/2014
Momenta Pharmaceuticals, Inc. (MNTA)' Necuparanib Receives Fast Track Designation From The FDA For The Treatment Of Patients With Metastatic Pancreatic Cancer 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Ampio Pharmaceuticals, Inc. (AMPE) Announces Results Of The Open Label Portion Of The Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Osteoarthritis Of The Knee At Week Twenty Of The Trial 12/1/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
TG Therapeutics, Inc. (MHA) Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib (Imbruvica) For Patients With Select B-Cell Malignancies 12/1/2014
Unum Therapeutics Announces Start Of First Phase I Clinical Trial Of Cellular Immunotherapy Targeting CD20+ Chronic Lymphocytic Leukemia And Non-Hodgkin Lymphoma 12/1/2014
Data Published By Researchers From Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity Through Previously Unidentified Mechanism 12/1/2014
ABIVAX Successfully Completes First-In-Man Study Of ABX464, A Highly Differentiated Small Molecule Targeting HIV 12/1/2014
GlaxoSmithKline (GSK), NIH Report Positive Ebola Vaccine Phase 1 Trial 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 11/26/2014
Synthon Initiates Treatment Of First Patients In Phase I Trial Of Anti-HER2 ADC SYD985 Based On Its Proprietary Linker-Drug Platform 11/25/2014
$1 Billion Oncology Alliance Between Menarini Group & Oxford BioTherapeutics Initiates First-In-Human Study Of Enhanced Antibody For Treatment Of Acute Myeloid Leukemia 11/25/2014
Juno Therapeutics (JUNO) T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 11/25/2014



//-->